These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26033698)

  • 1. Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference.
    Hochhaus G; Davis-Cutting C; Oliver M; Lee SL; Lyapustina S
    AAPS J; 2015 Sep; 17(5):1305-11. PubMed ID: 26033698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.
    Forbes B; Bäckman P; Christopher D; Dolovich M; Li BV; Morgan B
    AAPS J; 2015 Jul; 17(4):837-52. PubMed ID: 25940082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of Brazilian Requirements for Therapeutic Equivalence of Orally Inhaled and Nasal Drug Products.
    Silva MC; Costa HS; Valadares BN; Grecchi L; Nagao L; Santos GML
    AAPS PharmSciTech; 2019 Jun; 20(6):235. PubMed ID: 31236849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report.
    Evans C; Cipolla D; Chesworth T; Agurell E; Ahrens R; Conner D; Dissanayake S; Dolovich M; Doub W; Fuglsang A; García Arieta A; Golden M; Hermann R; Hochhaus G; Holmes S; Lafferty P; Lyapustina S; Nair P; O'Connor D; Parkins D; Peterson I; Reisner C; Sandell D; Singh GJ; Weda M; Watson P
    J Aerosol Med Pulm Drug Deliv; 2012 Jun; 25(3):117-39. PubMed ID: 22413806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.
    Lee SL; Saluja B; García-Arieta A; Santos GM; Li Y; Lu S; Hou S; Rebello J; Vaidya A; Gogtay J; Purandare S; Lyapustina S
    AAPS J; 2015 Sep; 17(5):1285-304. PubMed ID: 26002510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences.
    Lu D; Lee SL; Lionberger RA; Choi S; Adams W; Caramenico HN; Chowdhury BA; Conner DP; Katial R; Limb S; Peters JR; Yu L; Seymour S; Li BV
    AAPS J; 2015 May; 17(3):546-57. PubMed ID: 25758352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products.
    Newman B; Witzmann K
    Pharmaceut Med; 2020 Apr; 34(2):93-102. PubMed ID: 32112304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Focus and Regulatory Considerations for Inhalation Device Design: Report from the 2015 IPAC-RS/ISAM Workshop.
    Roche N; Scheuch G; Pritchard JN; Nopitsch-Mai C; Lakhani DA; Saluja B; Jamieson J; Dundon A; Wallace R; Holmes S; Cipolla D; Dolovich MB; Shah SA; Lyapustina S
    J Aerosol Med Pulm Drug Deliv; 2017 Feb; 30(1):1-13. PubMed ID: 27537608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Regulatory Developments for Orally Inhaled and Nasal Drug Products.
    Santos C; Marco G; Nagao LM; Castro E; Chesworth T
    AAPS PharmSciTech; 2018 Oct; 19(7):3134-3140. PubMed ID: 30128799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhalation devices and patient interface: human factors.
    Leiner S; Parkins D; Lastow O
    AAPS J; 2015 Mar; 17(2):457-61. PubMed ID: 25589457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of regulations for bioequivalence assessment of locally acting orally inhaled drug products for the United States, Europe, Canada, and India.
    Patil PP; Pawar AP; Mahadik KR; Gaikwad VL
    Expert Opin Drug Deliv; 2021 Dec; 18(12):1843-1855. PubMed ID: 34814778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A European perspective on orally inhaled products: in vitro requirements for a biowaiver.
    García-Arieta A
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):419-29. PubMed ID: 25238116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
    Mayers I; Bhutani M
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.
    Adams WP; Ahrens RC; Chen ML; Christopher D; Chowdhury BA; Conner DP; Dalby R; Fitzgerald K; Hendeles L; Hickey AJ; Hochhaus G; Laube BL; Lucas P; Lee SL; Lyapustina S; Li B; O'Connor D; Parikh N; Parkins DA; Peri P; Pitcairn GR; Riebe M; Roy P; Shah T; Singh GJ; Sharp SS; Suman JD; Weda M; Woodcock J; Yu L
    J Aerosol Med Pulm Drug Deliv; 2010 Feb; 23(1):1-29. PubMed ID: 20131983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Orally Inhaled Drug Products.
    Hochhaus G; Horhota S; Hendeles L; Suarez S; Rebello J
    AAPS J; 2015 May; 17(3):769-75. PubMed ID: 25762449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biocompatibility Considerations for Orally Inhaled and Nasal Drug Products and Other Drug--Device Combination Products.
    Stults CLM; Lanning CL; Nagao LM; Conners J
    PDA J Pharm Sci Technol; 2024 Feb; 78(1):125-139. PubMed ID: 37973193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of distinctions and parallels between the US and EU guidelines for determination of comparative effectiveness and safety of the orally inhaled drug products.
    Singh GJP
    Eur J Pharm Sci; 2024 Oct; 201():106872. PubMed ID: 39117248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for the Forced Expiratory Volume in 1 Second-Based Comparative Clinical Endpoint Bioequivalence Studies for Orally Inhaled Drug Products.
    Lee J; Feng K; Conti DS; Walenga R; Wientjes M; Wang H; Newman B; Han L; Dhapare S; Bielski E; Babiskin A; Wu F; Donnelly M; Kim MJ; Jiang W; Luke MC; Fang L; Zhao L
    Clin Pharmacol Ther; 2022 Nov; 112(5):982-989. PubMed ID: 35133652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foreign particles testing in orally inhaled and nasal drug products.
    Blanchard J; Coleman J; Hayling CD; Ghaderi R; Haeberlin B; Hart J; Jensen S; Malcolmson R; Mittelman S; Nagao LM; Sekulic S; Snodgrass-Pilla C; Sundahl M; Thompson G; Wolff R; ;
    Pharm Res; 2004 Dec; 21(12):2137-47. PubMed ID: 15648243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling and simulation of biopharmaceutical performance.
    Zhang X; Lionberger RA
    Clin Pharmacol Ther; 2014 May; 95(5):480-2. PubMed ID: 24747237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.